Search

Beam Therapeutics Inc

Fechado

SetorSaúde

26.72 1.17

Visão Geral

Variação de preço das ações

24h

Atual

Mín

26.2

Máximo

27.09

Indicadores-chave

By Trading Economics

Rendimento

-28M

-123M

Vendas

-31M

490K

EPS

-1.18

Margem de lucro

-25,036.327

Funcionários

540

EBITDA

-36M

-125M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+95.81% upside

Dividendos

By Acuity

Próximos Ganhos

2 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

152M

2.8B

Abertura anterior

25.55

Fecho anterior

26.72

Sentimento de Notícias

By Acuity

50%

50%

171 / 340 Ranking em Healthcare

Beam Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

13 de ago. de 2026, 23:01 UTC

Beam Therapeutics Inc. shares are higher in after-market trading, reflecting notable upward momentum since Thursday's close, despite no specific news identified.

12 de ago. de 2026, 20:06 UTC

Beam Therapeutics Inc. shares are lower today, continuing a trend of declines since Tuesday's close amid broader market uncertainties and lower U.S. Treasury yields.

11 de ago. de 2026, 23:06 UTC

Beam Therapeutics shares are higher in after-market trading, following a session peak. No specific news was identified to explain the price movement.

5 de ago. de 2026, 19:52 UTC

Correlated Moves

Beam Therapeutics Inc is trading lower as broader market sentiment weakens. The decline follows disappointing ADP employment data, which missed expectations significantly.

4 de ago. de 2026, 23:06 UTC

Beam Therapeutics Inc. shares are lower in after-market hours, following a session low shortly after the open, despite three consecutive higher daily closes.

3 de ago. de 2026, 19:16 UTC

Correlated Moves
News

Beam Therapeutics is rising amid a broader market rally, with a market cap of $2.64 billion and $1.2 billion in liquidity to support operations.

31 de jul. de 2026, 19:16 UTC

Correlated Moves

Beam Therapeutics shares are lower, reflecting a decline in first-quarter results and broader sector weakness. The stock remains near the lower end of its one-month range.

30 de jul. de 2026, 23:06 UTC

Beam Therapeutics Inc shares are higher in after-hours trading, advancing since Thursday's close, despite remaining below the 20-day moving average.

29 de jul. de 2026, 22:51 UTC

Beam Therapeutics shares are lower in after-market hours following a volatile session, amid broader market uncertainty after the Federal Reserve's interest rate decision.

28 de jul. de 2026, 23:51 UTC

Beam Therapeutics Inc shares are lower in after-market trading, experiencing unusual volatility amid broader market declines and positioned below its 20-day moving average.

27 de jul. de 2026, 23:06 UTC

Beam Therapeutics Inc shares are higher in after-market hours, despite a broader decline in trading. No specific news was identified to explain the increase.

24 de jul. de 2026, 19:26 UTC

Event
Correlated Moves

Beam Therapeutics is declining today, reflecting broader market trends, with the Russell 2000 Index down. The stock remains below its 20-day moving average.

23 de jul. de 2026, 09:51 UTC

News

Beam Therapeutics is higher in pre-market trading, driven by significant upcoming clinical milestones, including the global BEAM-302 trial and an FDA application for risto-cel.

22 de jul. de 2026, 23:46 UTC

Beam Therapeutics shares higher in after-market trading, advancing since Wednesday's close. The stock remains below its 20-day moving average amid broader market influences.

21 de jul. de 2026, 18:06 UTC

Correlated Moves

Beam Therapeutics shares are higher today, reflecting positive sentiment in small-cap stocks amid anticipation of upcoming earnings results from major companies.

20 de jul. de 2026, 23:56 UTC

Beam Therapeutics Inc is higher in after-market trading, showing notable strength since Monday's close. No specific news was identified to explain the movement.

Comparação entre Pares

Variação de preço

Beam Therapeutics Inc Previsão

Preço-alvo

By TipRanks

95.81% parte superior

Previsão para 12 meses

Média 52.3 USD  95.81%

Máximo 80 USD

Mínimo 26 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Beam Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

11 ratings

10

Comprar

1

Manter

0

Vender

Sentimento

By Acuity

171 / 340 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
help-icon Live chat